Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Reviews in gastroenterological disorders

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 15580149
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Adverse events of biologic or small molecule therapies in clinical trials for inflammatory bowel disease: A systematic review and meta-analysis

  2024cites this paper
• AN ADVANCED REVIEW ON DIAGNOSIS AND TREATMENT AND EXTRA-INTESTINAL MANIFESTATIONS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE

  2021cites this paper
• Citationally Enhanced Semantic Literature Based Discovery

  2019cites this paper
• Immunomodulatory tetracyclines: Facing the complexity of intestinal inflammation

  2017cites this paper
• Cyclophosphamide Pulse Therapy in Severe Refractory Crohn's Disease: A Retrospective Multicenter Case Series

  2017cites this paper
• Comparable outcomes of the consistent use versus switched use of anti- tumor necrosis factor agents in postoperative recurrent Crohn’s disease following ileocolonic resection

  2016cites this paper
• Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments

  2015cites this paper
• Pathological Contribution of Spinal Macrophage Migration Inhibitory Factor to Neuropathic Hypersensitivity through Interacting with TNF-α in the Rat

  2014cites this paper
• Gammaglobulins, autoantibodies, therapeutic antibodies and anti‐drug antibodies in rheumatoid arthritis

  2014cites this paper
• Biologic Agents for Inflammatory Bowel Disease (The Current, the Future and the Controversy)

  2012cites this paper
• Maintenance treatment with infliximab for the management of Crohn’s disease in adults

  2009cites this paper
• Les agents biologiques et l’hidradénite suppurée (la maladie de Verneuil à l’ère des produits biologiques)

  2008cites this paper
• Drug Safety Evaluation

  2008cites this paper
• Maintenance treatment with in fl iximab for the management of Crohn ’ s disease in adults

  2008cites this paper
• Regulation of Immunopathology in Mycobacterium tuberculosis infection

  2008cites this paper
• Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes.

  2008cites this paper
• What are the guidelines for using biologics in pediatric patients?

  2008cites this paper
• Treatment with biologic therapies and the risk of cancer in patients with IBD

  2007cites this paper
• Respiratory sinus arrhythmia and diseases of aging: obesity, diabetes mellitus, and hypertension.

  2007cites this paper
• Practical guidelines for the treatment of inflammatory bowel disease.

  2007cites this paper
• Infliximab and the risk of latent viruses reactivation in active Crohn's disease

  2007cites this paper
• Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials.

  2007cites this paper
• Acute p38-Mediated Modulation of Tetrodotoxin-Resistant Sodium Channels in Mouse Sensory Neurons by Tumor Necrosis Factor-α

  2006cites this paper
• Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

  2006cites this paper
• The Emerging Use of TNF-α Inhibitors in Orbital Inflammatory Disease

  2006cites this paper
• PREDICTING, MEASURING, AND MAINTAINING RESPONSE TO TNF-α ANTAGONISTS IN INFLAMMATORY BOWEL DISEASE

  2006cites this paper
• Manifestaciones articulares de las enfermedades intestinales

  2006cites this paper
• Adalimumab: uma nova opção na doença de crohn?

  2006cites this paper
• Off-Label Drug Uses

  2006cites this paper
• RELACIÓN ESTRUCTURA-ACTIVIDAD DE LOS FLAVONOIDES COMO AGENTES ANTIINFLAMATORIOS INTESTINALES

  2006cites this paper
• A new transcription factor that regulates TNF‐&agr; gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC

  2006cites this paper
• TNF blockade: an inflammatory issue.

  2006cites this paper
• Paeonol attenuates TNBS-induced colitis by inhibiting NF-kappaB and STAT1 transactivation.

  2006cites this paper
• Biological Approach in the Treatment of Crohn’s Disease

  2006cites this paper
• Biologics For Hidradenitis Suppurativa (Verneuil’s Disease in the Era of Biologics)

  2006cites this paper
• Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha.

  2006cites this paper
• Manifestations articulaires des affections intestinales

  2006cites this paper
• BEYOND MOLECULAR BIOLOGY: IMPROVING QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE

  2005cites this paper
• Molekulare Therapie in der Gastroenterologie und Hepatologie

  2005cites this paper
• Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature.

  2005cites this paper
• 10 TNF Blockade : An Inflammatory Issue

  2005cites this paper
• Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies

  2005cites this paper
• Role of the Immune system in chronic pain

  2005cites this paper
• TRANSLATING MOLECULAR BIOLOGY INTO CLINICAL PRACTICE: THE ROLE OF TNF-α IN CROHN'S DISEASE

  2005cites this paper